Ganaxolone vs Stiripentol

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: GABA-A receptor · full Epilepsy pipeline

Ganaxolone

Marketed by Immedica Pharma AB

Approved in Epilepsysmall molecule
Partial signal

NCT01963208 · Phase 3 · completed

The primary phase was well controlled, with randomized quadruple blinding, placebo comparison, and 350 analyzed participants, and it used the clinical endpoint of change in seizure frequency. However, the primary endpoint was missed: the difference between ganaxolone and placebo was not statistically significant (p=0.1788), so the study provides well-designed but inconclusive evidence.

Reported efficacy

Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes); Percentage of Participants With no Progression to Intravenous (IV) Anesthesia for 36 Hours Following Investigational Product (IP) Initiation (Up to 36 hours after IP initiation); Number of Participants With Treatment Emergent Adverse Events (Up to 4 weeks after IP initiation): Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741) (mixed)

Result source: NCT04391569

Stiripentol

Marketed by Biocodex

Approved in Epilepsysmall molecule
Weak signal

NCT07176832 · Phase 1 · completed

This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGanaxoloneStiripentol
Seizure frequency, % change-7.5% vs 13.6%−21.1 vs placebowk 4 · n 64NCT05323734
4 other results
  • -61.5% vs -24.0% wk 17 · n 10 · Phase 2 · primary NCT03865732
  • -17.6% vs 2.0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • -12.1% vs 4.6% wk 10 · n 95 · Phase 2 · secondary NCT00465517
  • -35.9% vs -18.7% wk 17 · n 6 · Phase 2 · secondary NCT03865732
—Not reported
50% responder rate18.8% vs 12.3%+6.5 vs placebowk 16 · n 64NCT05323734
3 other results
  • 23.5% vs 14.3% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 25.5% vs 12.2% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 50% vs 36.4% wk 17 · n 10 · Phase 2 · secondary NCT03865732
—Not reported
Seizure freedom0% vs 2.2%−2.2 vs placebowk 10 · n 95NCT00465517
2 other results
  • 1% vs 0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 16.8% vs 8.3% wk 2 · n 95 · Phase 2 · secondary NCT00465517
—Not reported

Seizure frequency, % change

Ganaxolone
-7.5% vs 13.6%−21.1 vs placebowk 4 · n 64NCT05323734
4 other results
  • -61.5% vs -24.0% wk 17 · n 10 · Phase 2 · primary NCT03865732
  • -17.6% vs 2.0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • -12.1% vs 4.6% wk 10 · n 95 · Phase 2 · secondary NCT00465517
  • -35.9% vs -18.7% wk 17 · n 6 · Phase 2 · secondary NCT03865732
Stiripentol
—Not reported

50% responder rate

Ganaxolone
18.8% vs 12.3%+6.5 vs placebowk 16 · n 64NCT05323734
3 other results
  • 23.5% vs 14.3% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 25.5% vs 12.2% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 50% vs 36.4% wk 17 · n 10 · Phase 2 · secondary NCT03865732
Stiripentol
—Not reported

Seizure freedom

Ganaxolone
0% vs 2.2%−2.2 vs placebowk 10 · n 95NCT00465517
2 other results
  • 1% vs 0% wk 10 · n 98 · Phase 2 · secondary NCT00465517
  • 16.8% vs 8.3% wk 2 · n 95 · Phase 2 · secondary NCT00465517
Stiripentol
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Stiripentol: no structured comparison results are available for Epilepsy.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Ganaxolone: 4 of 4 rows · Stiripentol: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGanaxolone
Dropout rate
4.2%Double Blind: Cohort 1 - Ganaxolona
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
24.6%Double Blind: Cohort 2 - Ganaxolon
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Ganaxolone in Double-b
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Placebo in Double-blin
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
41.2%
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
14.1%
NCT05323734 · Phase 3 · registry result, not featured evidence
10%
NCT03865732 · Phase 2 · registry result, not featured evidence
12.5%High
NCT03350035 · Phase 2 · registry result, not featured evidence
40%Low
NCT03350035 · Phase 2 · registry result, not featured evidence
0%Medium
NCT03350035 · Phase 2 · registry result, not featured evidence
42.9%CDKL5
NCT02358538 · Phase 2 · registry result, not featured evidence
100%CSWS
NCT02358538 · Phase 2 · registry result, not featured evidence
50%Lennox-Gastaut
NCT02358538 · Phase 2 · registry result, not featured evidence
45.5%PCDH19
NCT02358538 · Phase 2 · registry result, not featured evidence
95.1%
NCT00512317 · Phase 2 · registry result, not featured evidence
36.4%
NCT01002820 · Phase 2 · registry result, not featured evidence
12.2%
NCT00465517 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4.2%Double Blind: Cohort 1 - Ganaxolona
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
16.8%Double Blind: Cohort 2 - Ganaxolon
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Ganaxolone in Double-b
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—Open Label: Placebo in Double-blin
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
—
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
7.8%
NCT05323734 · Phase 3 · registry result, not featured evidence
10%
NCT03865732 · Phase 2 · registry result, not featured evidence
—High
NCT03350035 · Phase 2 · registry result, not featured evidence
—Low
NCT03350035 · Phase 2 · registry result, not featured evidence
—Medium
NCT03350035 · Phase 2 · registry result, not featured evidence
0%CDKL5
NCT02358538 · Phase 2 · registry result, not featured evidence
50%CSWS
NCT02358538 · Phase 2 · registry result, not featured evidence
10%Lennox-Gastaut
NCT02358538 · Phase 2 · registry result, not featured evidence
18.2%PCDH19
NCT02358538 · Phase 2 · registry result, not featured evidence
10.6%
NCT00512317 · Phase 2 · registry result, not featured evidence
9.1%
NCT01002820 · Phase 2 · registry result, not featured evidence
7.1%
NCT00465517 · Phase 2 · registry result, not featured evidence
Serious AEs
0%Double Blind: Cohort 1 - Ganaxolona
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
5%Double Blind: Cohort 2 - Ganaxolon
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
7.6%Open Label: Ganaxolone in Double-b
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
6.9%Open Label: Placebo in Double-blin
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
37.3%
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
7.8%
NCT05323734 · Phase 3 · registry result, not featured evidence
10%
NCT03865732 · Phase 2 · registry result, not featured evidence
25%High
NCT03350035 · Phase 2 · registry result, not featured evidence
40%Low
NCT03350035 · Phase 2 · registry result, not featured evidence
50%Medium
NCT03350035 · Phase 2 · registry result, not featured evidence
14.3%CDKL5
NCT02358538 · Phase 2 · registry result, not featured evidence
50%CSWS
NCT02358538 · Phase 2 · registry result, not featured evidence
20%Lennox-Gastaut
NCT02358538 · Phase 2 · registry result, not featured evidence
27.3%PCDH19
NCT02358538 · Phase 2 · registry result, not featured evidence
12.2%
NCT00512317 · Phase 2 · registry result, not featured evidence
9.1%
NCT01002820 · Phase 2 · registry result, not featured evidence
5.1%
NCT00465517 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
ataxia 12.5% (placebo 0%)
sedation 12.5% (placebo 0%)
somnolence 12.5% (placebo 9.5%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 16 more results
somnolence 22.3% (placebo 9.5%)
dizziness 19% (placebo 0%)
fatigue 11.7% (placebo 0%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
somnolence 7.6% (placebo 9.5%)
fatigue 5.7% (placebo 0%)
headache 5.7% (placebo 0%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
somnolence 16.8% (placebo 9.5%)
dizziness 15.6% (placebo 0%)
fatigue 8.7% (placebo 0%)
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
hypotension 23.5% (placebo 16.3%)
urinary tract infection 19.6% (placebo 8.2%)
hypothermia 9.8% (placebo 4.1%)
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
somnolence 28.1% (placebo 16.9%)
pyrexia 15.6% (placebo 16.9%)
fatigue 14.1% (placebo 9.2%)
NCT05323734 · Phase 3 · registry result, not featured evidence
somnolence 40% (placebo 27.3%)
aggression 20% (placebo 9.1%)
agitation 20% (placebo 0%)
NCT03865732 · Phase 2 · registry result, not featured evidence
High
somnolence 37.5%
hypercaprnia 25%
hypocalcaemia 25%
NCT03350035 · Phase 2 · registry result, not featured evidence
Low
hypotension 40%
haematuria 20%
pain 20%
NCT03350035 · Phase 2 · registry result, not featured evidence
Medium
hypokalaemia 25%
pain 25%
pneumonia 25%
NCT03350035 · Phase 2 · registry result, not featured evidence
pyrexia 71.4%
upper respiratory tract infection 42.9%
vomiting 42.9%
NCT02358538 · Phase 2 · registry result, not featured evidence
dizziness 50%
sinusitis 50%
somnolence 50%
NCT02358538 · Phase 2 · registry result, not featured evidence
fungal infection 20%
hypersomnia 20%
seizure 20%
NCT02358538 · Phase 2 · registry result, not featured evidence
pyrexia 63.6%
somnolence 54.5%
fatigue 36.4%
NCT02358538 · Phase 2 · registry result, not featured evidence
headache 21.1%
convulsion 16.3%
fatigue 16.3%
NCT00512317 · Phase 2 · registry result, not featured evidence
headache 18.2%
irritability 18.2%
aortic aneurysm 9.1%
NCT01002820 · Phase 2 · registry result, not featured evidence
dizziness 16.3% (placebo 8.2%)
fatigue 16.3% (placebo 8.2%)
somnolence 13.3% (placebo 2%)
NCT00465517 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 12 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ganaxolone

Seizure 50 28.1% (n=178) vs 22.7% (n=172) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 · converted to % from 50 Participants as posted
Seizure Free 0.05 vs 0.03 placebo months @ 14wk
absolute change · months
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 · converted to months from 1.47 days as posted
show 1 more result
0.05 vs 0.04 placebo months @ 14wk*
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3 · converted to months from 1.63 days as posted
Seizure Frequency -1.46 vs -0.33 placebo per 28 day @ 14wk
absolute change · per 28 day
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
show 1 more result
-1.67 vs -0.64 placebo per 28 day @ 14wk
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Seizure-free 1.12% (n=178) vs 0% (n=172) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
at Least One Seizure Free Period 17.98% (n=178) vs 18.02% (n=172) placebo @ 14wk
responder rate · % of participants
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
Time Spent Seizure-free 24% (n=178) vs 17.58% (n=172) placebo @ 14wk
absolute value · percentage points
Maintenance
NCT01963208 · Phase 3 · monotherapy · Epilepsy, Focal Onset Seizures · phase 3
SE Cessation 30 Min 79.59% (n=49) vs 12.77% (n=47) placebo @ 0.003wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
SE no Progression to IV Anesthesia 36 h 63.27% (n=49) vs 51.06% (n=47) placebo @ 0.2143wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
SE no Progression to IV Anesthesia 72h 51.02% (n=49) vs 46.81% (n=47) placebo @ 0.4286wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
Time to SE Cessation 0.07 vs 2.85 placebo hours
absolute value · hours
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
Treatment Escalation 24 h 55.1% (n=49) vs 80.85% (n=47) placebo @ 0.1429wk
responder rate · % of participants
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3
Time to Treatment Escalation 5.42 vs 2.32 placebo hours
absolute value · hours
NCT04391569 · Phase 3 · monotherapy · Epilepsy · phase 3

+ 41 further endpoints in the CSV export.

Developmental and Epileptic Encephalopathies

Shared mechanism: GABA-A receptor · full Developmental and Epileptic Encephalopathies pipeline

Ganaxolone

Marketed by Immedica Pharma AB

Approved in Developmental and Epileptic Encephalopathiessmall molecule
Partial signal

NCT03572933 · Phase 3 · completed

Marigold was a randomized, double-blind, placebo-controlled Phase 3 trial in 101 patients aged 2 to 21 with CDKL5 deficiency disorder. The primary endpoint was the percentage change in 28-day major motor seizure frequency over 17 weeks: -30.7% with ganaxolone vs -6.9% with placebo (p=0.0036), so the primary was met. Source: the peer-reviewed paper (Knight et al., Lancet Neurol 2022).

Reported efficacy

Summary of 28-day Seizure Frequency for Major Motor Seizure Types (End of the double-blind 17 week treatment period): Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022). (met)

Result source: NCT03572933

Stiripentol

Marketed by Biocodex

Approved in Developmental and Epileptic Encephalopathiessmall molecule
Weak signal

NCT07176832 · Phase 1 · completed

This is an open-label pharmacokinetic bioequivalence study comparing two formulations of the same already-marketed drug in healthy volunteers, not a controlled trial measuring clinical efficacy against a comparator or placebo.

No aligned efficacy figure on record for this race.

Results for Developmental and Epileptic Encephalopathies

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Stiripentol: no structured comparison results are available for Developmental and Epileptic Encephalopathies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Ganaxolone

Seizure Frequency Per 45.03 vs 55.5 placebo per day @ 17wk
absolute value · per day
17 week-post baseline phase (Median)
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3
Seizure-free 32.29 vs 36.17 placebo % of time @ 17wk
absolute value · % of time
17-week-Post-Baseline Phase
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3
Longest Seizure Free Interval 0 vs -0.15 placebo months @ 17wk
absolute change · months
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3 · converted to months from -0.02 days as posted
Available safety results

Ganaxolone

Dropout rate
4%
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3
Discontinued due to AEs
2%
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3
Serious AEs
12%
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3
Most frequent reported AEs
somnolence 36% (placebo 15.7%)
pyrexia 18% (placebo 7.8%)
seizure 14% (placebo 17.6%)
NCT03572933 · Phase 3 · monotherapy · CDKL5 Deficiency Disorder · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ganaxolone's landscape · Stiripentol's landscape